THE SPECIFIC FEATURES OF THE PHASE I OF CLINICAL INVESTIGATIONS OF DRUGS
摘要
This article discusses the possibility of clinical research of drugs, identifies the specific features of the phase I of clinical investigations.
关于作者
A. Savchenko
First MSMU named after I.M. Sechenov
俄罗斯联邦
俄罗斯联邦
G. Ramenskaya
First MSMU named after I.M. Sechenov
俄罗斯联邦
俄罗斯联邦
V. Kukes
First MSMU named after I.M. Sechenov
俄罗斯联邦
俄罗斯联邦
参考
1. Kola I, Landis J. Can the industry reduce attrition rates? // Nature Rev. Drug Disc. — 2004. — Vol. 3. — 711 p.
2. Lesko L, Atkinson A. Use of biomarkers and surrogate endpoints in drug development // Ann. Rev. Pharmacol. Toxicol. — 2001. — Vol. 41. — P. 347–366.
3. Bioavailability and bioequivalence // CPMP/EWP/QWP. — 1998. — 1401 p.
4. Shah R. QT interval in drug development // Br. J. Clin. Pharmacol. — 2002. — Vol. 54. — P. 188–202.
5. Estimating the safe starting dose for healthy volunteers. — FDA, 2005.
6. Toxicokinetics and exposure in toxicology studies // CPMP/ICH. — 1995. — 384 p.
7. Declaration of Helsinki. — World Medical Association, 1996.
8. Sibille M et al. Is phase 1 still safe? // Br. J. Clin. Pharmacol. — 2006. — Vol. 62. — P. 502–503.
评论
浏览:
227
Email this article 